Get the Stockscreener App
17.14
6.33%
1.02
After Hours:
17.20
0.06
+0.35%
Immunovant Inc stock is traded at $17.14, with a volume of 2.07M.
It is up +6.33% in the last 24 hours and up +3.82% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$16.12
Open:
$16.17
24h Volume:
2.07M
Relative Volume:
1.55
Market Cap:
$2.99B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-6.542
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+16.68%
1M Performance:
+3.82%
6M Performance:
-11.74%
1Y Performance:
-49.02%
1-Day Range:
$16.10
$17.35
1-Week Range:
$14.78
$17.35
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
17.14 | 2.81B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Visual analytics tools that track Immunovant Inc. performanceMarket Risk Report & Short-Term High Return Ideas - Newser
Real time breakdown of Immunovant Inc. stock performance2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What are the analyst revisions for SWINIs Immunovant Inc. stock a good investment in YEARPortfolio Profit Report & Stepwise Trade Signal Implementation - خودرو بانک
What to do if you’re stuck in Immunovant Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
Is Immunovant Inc. trending in predictive chart modelsWall Street Watch & Daily Stock Trend Watchlist - Newser
Real time social sentiment graph for Immunovant Inc.Trade Risk Report & Daily Stock Trend Reports - Newser
Is Immunovant Inc. a cyclical or defensive stockAnalyst Downgrade & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Is Immunovant Inc. affected by consumer sentimentChart Signals & Advanced Technical Analysis Signals - خودرو بانک
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
What’s next for Immunovant Inc. stockWeekly Trend Summary & Trade Opportunity Analysis Reports - خودرو بانک
Is Immunovant Inc. stock good for income investors2025 Bull vs Bear & Accurate Intraday Trading Signals - خودرو بانک
Applying Elliott Wave Theory to Immunovant Inc.Analyst Upgrade & Technical Pattern Based Signals - Newser
Using data tools to time your Immunovant Inc. exitGlobal Markets & Risk Managed Investment Signals - Newser
Is Immunovant Inc. stock entering bullish territoryLayoff News & Community Verified Watchlist Alerts - Newser
Earnings visualization tools for Immunovant Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Immunovant Inc. stock outlook for YEARPortfolio Performance Summary & Safe Entry Trade Signal Reports - Newser
Risk vs reward if holding onto Immunovant Inc.Bond Market & Daily Technical Forecast Reports - Newser
Immunovant reports promising remission data for Graves’ disease therapy By Investing.com - Investing.com Australia
What is Immunovant Inc.’s book value per shareJuly 2025 Update & Daily Volume Surge Trade Alerts - خودرو بانک
Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - The Globe and Mail
Immunovant’s Batoclimab: A Game-Changer in the Evolving Graves’ Disease Market - AInvest
Momentum divergence signals in Immunovant Inc. chart2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Is Immunovant Inc. a strong growth stockMarket Volume Summary & Consistent Income Trade Recommendations - خودرو بانک
What machine learning models say about Immunovant Inc.2025 Market Trends & Verified Entry Point Detection - Newser
Immunovant stock rises as Oppenheimer reiterates Outperform on Graves’ data - Investing.com
What institutional flow reveals about Immunovant Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
Combining price and volume data for Immunovant Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser
Why Immunovant Stock Blasted Higher Today - AOL.com
Can momentum traders help lift Immunovant Inc.Portfolio Return Report & Verified Chart Pattern Trade Signals - Newser
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener
What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener
Immunovant Announces Promising Graves’ Disease Study Results - TipRanks
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times
Immunovant reports promising remission data for Graves’ disease therapy - Investing.com
Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative
Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative
80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan
Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser
How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser
Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser
Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):